No drug designed by artificial intelligence has ever entered a phase 3 clinical trial, the final hurdle before regulatory approval. This could soon change, however. A small molecule from InSilico Medicine that targets a chronic lung disease could…
InSilico’s rentosertib could become first AI-designed drug to reach phase 3 trials and change drug discovery forever
